Journal profile · Biotechnology & Applied Microbiology
Cancer Gene Therapy
ISSN 0929-1903 · eISSN 1476-5500 · Springer Nature · ENGLAND · Monthly · Founded 1999
Cancer Gene Therapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 6.46; hybrid open access; APC about USD 4,990; median 172 days to acceptance (93 articles, last 24 months); community-reported acceptance: fairly easy; 130 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Gene Therapy is published by Springer Nature and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Virus-based gene therapy research, RNA Interference and Gene Delivery and CAR-T cell therapy research, together about 42.5% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair. Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.
From the journal's Aims & Scope
Research area (LetPub): Biotechnology & Applied Microbiology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology21.3%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology10.9%
- CAR-T cell therapy researchMedicine10.3%
- Immunotherapy and Immune ResponsesImmunology and Microbiology7.1%
- Cancer Research and TreatmentsBiochemistry, Genetics and Molecular Biology6.8%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology4%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology3.6%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 3 |
| Minor | Genetics & Heredity | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 2 |
| Minor | Oncology | Zone 3 |
| Minor | Genetics & Heredity | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 2 |
| Minor | Genetics & Heredity | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCurrent ContentsPublisher website
Other: Google Scholar, EBSCO, ProQuest, OCLC, BIOSIS, Summon by ProQuest, EBSCO Discovery Service, EBSCO Academic Search
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.46LetPub ·
- Impact factor (publisher) 2025
- 6.4Publisher website ·
- 5-year impact factor (publisher) 2025
- 5.9Publisher website ·
- CiteScore 2026-06
- 11.1LetPub ·
- SJR 2026-06
- 1.75LetPub ·
- SJR (publisher) 2025
- 1.75Publisher website ·
- SNIP 2026-06
- 1.12LetPub ·
- SNIP (publisher) 2025
- 1.12Publisher website ·
- h-index
- 80LetPub ·
- h-index
- 112OpenAlex ·
- i10-index
- 2,161OpenAlex ·
- 2-year mean citedness
- 7.33OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 44.92%LetPub ·
Volume
- Articles per year
- 119LetPub ·
- Downloads per year (publisher) 2025
- 1,340,693Publisher website ·
Articles by year OpenAlex count · 3,005 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 85 | 35 | 52 |
| 2025 | 130 | 65 | 530 |
| 2024 | 146 | 79 | 2,063 |
| 2023 | 140 | 75 | 2,117 |
| 2022 | 170 | 91 | 3,161 |
| 2021 | 137 | 72 | 4,178 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
172 daysMedian, submission to acceptance · P25–P75 133 days – 232 days
- Acceptance to online
- median 14 days (93 articles)
- Submission to online
- median 190 days
- Sample
- 93 articles with submission and acceptance dates (250 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 5 daysPublisher website ·
- Submission to acceptance
- 149 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,990 / EUR 4,090 / GBP 3,390 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted6
- brief communicationsTypes of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensit…Length not stated
- case reportsTypes of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensit…Length not stated
- industry perspectivesTypes of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensit…Length not stated
- letters to the editorTypes of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensit…Length not stated
- original research articlesTypes of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensit…Length not stated
- review articlesTypes of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensit…Length not stated
Policy excerpts from the journal's websiteOpen access
- Open access
RSS web feed available Model summary
Cancer Gene Therapy now provides its latest table of contents as an RSS web feed. This allows users with an RSS reader to receive automatic updates whenever new content is added to these pages.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 1999
- ISSN
- 0929-1903
- Electronic ISSN
- 1476-5500
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cancer Gene Therapy
What CAS zone is Cancer Gene Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Gene Therapy is in Zone 3 of Medicine, and in Zone 3 of the minor category Biotechnology & Applied Microbiology / Genetics & Heredity / Medicine, Research & Experimental / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Gene Therapy?
The latest impact factor listed by LetPub is 6.46; CiteScore 11.1, h-index 112.
How long does peer review take at Cancer Gene Therapy?
Based on the dates recorded on 93 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 172 days (interquartile range 133–232 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Cancer Gene Therapy?
According to LetPub and DOAJ records, Cancer Gene Therapy is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase and Current Contents; that list has not been checked against each database.
Is Cancer Gene Therapy open access, and what is the APC?
Cancer Gene Therapy is a hybrid journal. For open-access publication: APC about USD 4,990.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .